Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Nat Rev Drug Discov. 2018 Apr;17(4):261-279. doi: 10.1038/nrd.2017.243. Epub 2018 Jan 12.
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
mRNA 疫苗因其高效力、快速开发能力以及低成本制造和安全给药的潜力,代表了一种有前途的传统疫苗方法的替代方案。然而,直到最近,其应用一直受到 mRNA 体内递送不稳定和效率低下的限制。最近的技术进步在很大程度上克服了这些问题,针对传染病和多种癌症的多种 mRNA 疫苗平台在动物模型和人类中均显示出令人鼓舞的结果。本综述详细介绍了 mRNA 疫苗,并考虑了推进这一有前途的疫苗平台广泛应用于治疗的未来方向和挑战。